Detalhe da pesquisa
1.
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Blood
; 139(15): 2306-2315, 2022 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35167655
2.
Histologic correlates of "Choroidal abnormalities" in Neurofibromatosis type 1 (NF1).
Acta Neuropathol
; 147(1): 71, 2024 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607446
3.
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Br J Dermatol
; 190(2): 216-225, 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37877514
4.
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Clin Trials
; 21(1): 67-72, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269078
5.
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Clin Trials
; 21(1): 51-66, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37937606
6.
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Clin Trials
; 21(1): 29-39, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37772407
7.
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
Genet Med
; 25(2): 100324, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36565307
8.
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
J Biol Chem
; 296: 100157, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33273014
9.
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.
Oncologist
; 27(7): 518-524, 2022 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35443045
10.
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Genet Med
; 24(9): 1967-1977, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35674741
11.
Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis.
Am J Med Genet A
; 188(8): 2413-2420, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35638454
12.
Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis.
Am J Med Genet A
; 188(9): 2672-2683, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678462
13.
A practical guide to neuro-oncology fellowship.
J Neurooncol
; 156(1): 73-79, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34855097
14.
Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.
Am J Hum Genet
; 102(1): 69-87, 2018 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29290338
15.
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Genet Med
; 23(8): 1506-1513, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34012067
16.
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Acta Neuropathol
; 141(1): 101-116, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33025139
17.
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
Proc Natl Acad Sci U S A
; 115(9): E2077-E2084, 2018 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29440379
18.
Are Some Randomized Clinical Trials Impossible?
J Pediatr Orthop
; 41(1): e90-e93, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32852366
19.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Oncologist
; 25(7): e1109-e1116, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32272491
20.
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
Am J Med Genet A
; 179(6): 1091-1097, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30908877